Coronavirus disease 2019 vaccination in patients with autoimmune diseases
- VernacularTitle:自身免疫疾病患者的新型冠状病毒肺炎疫苗接种
- Author:
Yue GUAN
1
;
Fei MU
1
;
Wei ZHANG
1
;
Yi QIAO
1
;
Congcong WANG
1
;
Sunin CHEN
1
;
Guiping GUO
1
;
Jingwen WANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Autoimmune diseases; SARS-CoV-2; Vaccination; COVID-19 vaccines
- From: Adverse Drug Reactions Journal 2021;23(7):342-347
- CountryChina
- Language:Chinese
- Abstract: Benifits outweigh the risks for patients with autoimmune disease (AID) in remission period to be vaccinated with coronavirus disease 2019 (COVID-19) vaccines. The mRNA vaccines, inactivated vaccines, and recombinant protein subunit vaccines are safe for AID patients, whereas the safety of recombinant adenovirus vector-based vaccines is still uncertain. Some drugs for the treatment of AID may reduce the immune response of the body to the COVID-19 vaccines and affect the immune efficacy of the vaccine, which may be related to the timing of vaccination. Based on several published relevant guidelines and recommendations for the COVID-19 vaccines in AID patients, this article elaborates on vaccination problems to be paid attention to in patients with AID treated with different drugs.
